LATEST ARTICLES
- Novartis’ new rare disease drug Vijoice named as an ‘empty vessel poised to be filled’
- GSK, IQVIA team up on ‘Vaccine Track’ to spotlight shot trends across the US
- New CEO Maselli extends Catalent’s expansion blitz with $475M buyout of CDMO Metrics
- CPHI FRANKFURT
- Amid Wegovy’s supply woes, Novo Nordisk sees surging demand for its original obesity drug Saxenda
